Aulos Bioscience CEO Aron Knickerbocker discusses his company's antibody approach to IL-2 at #ASCO24

blonca9
Jun 2, 2024
1 min read

Updated: Nov 9, 2024

Aron Knickerbocker describes the benefits of focusing on the CD-25 binding portion of IL-2 and discusses some data presented at ASCO. He believes this program is the first AI designed human antibody to enter the clinic.

Recent Posts

See All

Bay Area based Nosis Bio is leveraging AI to get its gene silencers specifically to precise cell types - it recently announced a development candidate to tackle fibrosis

Checking in with Alector CEO Arnon Rosenthal ahead of a pivotal trial readout for latozinemab in frontotemporal dementia in the fourth quarter

IDEAYA Biosciences is at the forefront of precision oncology - we discuss the pipeline, including a key pivotal trial that will read out for Darovasertib by the end of the year

Aulos Bioscience CEO Aron Knickerbocker discusses his company's antibody approach to IL-2 at #ASCO24

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight